Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Sol-Gel Technologies
Deal Size : $16 million
Deal Type : Licensing Agreement
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Details : The agreement aims for the sale and license of the U.S. rights to Epsolay, a topical cream containing encapsulated benzoyl peroxide, and Twyneo, a FDC of encapsulated benzoyl peroxide and tretinoin.
Product Name : Epsolay
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2025
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Sol-Gel Technologies
Deal Size : $16 million
Deal Type : Licensing Agreement
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Mayne Pharma for Women’s Health Leadership
Details : Through the acquisition, Cosette will utilize market-leading commercial products focused on women’s health, including Annovera (segesterone acetate & ethinyl estradiol) to prevent preganancy.
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : TherapeuticsMD
Deal Size : $225.7 million
Deal Type : Licensing Agreement
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : $140.0 million
March 01, 2023
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : TherapeuticsMD
Deal Size : $225.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $105.0 million
Deal Type : Acquisition
Dr Reddy's to Acquire Mayne Pharma US Generic Portfolio for $105 Million
Details : Through the acquisition, Reddy will capitalize on the generic prescription portfolio, including products like Aspirin-Generic (aspirin), to prevent heart attacks and strokes.
Product Name : Aspirin-Generic
Product Type : Other Small Molecule
Upfront Cash : $90.0 million
February 27, 2023
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : $105.0 million
Deal Type : Acquisition
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : $225.7 million
Deal Type : Agreement
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : $140.0 million
April 12, 2022
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : $225.7 million
Deal Type : Agreement
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Three Additional Strengths Of Isotretinoin Capsules
Details : Upsher-Smith’s product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules in 10 mg, 20 mg, 30 mg and 40 mg strengths used to treat severe cystic acne.
Product Name : Isotretinoin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data shows treatment with NEXTSTELLIS®,1 a novel, investigational combined oral contraceptive containing drospirenone and estetrol, resulted in less changes in endocrine markers, including lower increases in hormone binding globulins vs COCs based o...
Product Name : Nextstellis
Product Type : Hormone
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published
Details : NEXTSTELLIS (drospirenone and estetrol tablets) indicated for use by females of reproductive potential to prevent pregnancy. Nextstellis® has been granted marketing exclusivity as a new chemical entity from the US Food and Drug Administration (FDA).
Product Name : Nextstellis
Product Type : Hormone
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations
Details : NEXTSTELLIS is the first contraceptive pill containing E4, a new naturally occurring estrogen with a unique mechanism of action that offers potential advantages over other estrogens.
Product Name : Nextstellis
Product Type : Hormone
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Drospirenone,Estetrol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mayne Pharma Launches Chlorzoxazone Tablet in the United States
Details : FDA has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, in the United States.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
